Whole-mount Immunohistochemistry to Visualize Mouse Embryonic Dermal Lymphatic Vasculature

Materials and Reagents

1. 12-well plate

2. 6-well plate

3. 24-well plate

4. Sylgard 184 silicone elastomer kit (Fisher Scientific, catalog number: NC9285739)

5. Insect pin (Fine Science Tools, catalog number: 26002-20)

6. Heparin (Millipore Sigma, catalog number: H3393): resuspend in water at 50 mg/ml, aliquot, and store at -20°C)

7. Sodium deoxycholate (VWR, catalog number: 0613-100g): to make 10% stock solution dissolve 5 g in 30 ml water, add water to 50 ml, and store at room temperature protected from light.

8. Microscope slides (Denville Scientific INC, catalog number: M1021)

9. Wax pen (Vector, catalog number: H-4000)

10. Microscope cover glass (Fisher Scientific, catalog number: 12-545-M)

11. Mounting medium (Electron Microscopy Sciences, catalog number: 17985-01-02-03)

12. Goat anti mVEGFR3 (R&D System, catalog number: AF743)

13. Rat anti mCD31 (BD Pharmingen, catalog number: 553370)

14. Rabbit anti PROX1 (AngioBio Co. catalog number: 11-002)

15. Rat anti mNRP2 (R&D System, catalog number: AF567)

16. Goat anti hPROX1 (R&D System, catalog number: AF2727)

17. Goat anti mVEGFR2 (R&D System, catalog number: AF644)

18. Goat anti mLYVE-1 (R&D System, catalog number: AF2125)

19. Sheep anti mFOXC2 (R&D System, catalog number: AF6989)

20. Rabbit anti mClaudin 5 (ThernoFisher, catalog number: 34-1600)

21. CY3-conjugated Mouse anti-Rabbit (Jackson ImmunoResearch Laboratories, catalog number: 711-165-152)

22. Alexa488-conjugated Donkey anti-Goat (Jackson ImmunoResearch Laboratories, catalog number: 705-545-147)

23. CY5-conjugated Donkey anti-Rat (Jackson ImmunoResearch Laboratories, catalog number: 712-175-150)

24. CY3-conjugated Donkey anti-Sheep (Jackson ImmunoResearch Laboratories, catalog number: 713-165-147)

25. Rat anti mCD144 (BD Pharmingen, catalog number: 550548)

26. 20× PBS (see Recipes)

27. 20% paraformaldehyde (PFA) (see Recipes)

28. 10% Triton X-100 (see Recipes)

29. PBST (see Recipes)

30. PBST/20% DMSO (see Recipes)

31. 10% Tween 20 (see Recipes)

32. 10% NP40 (see Recipes)

33. PTTDND (see Recipes)

34. 1 M glycine (see Recipes)

35. PTDG (see Recipes)

36. Blocking buffer (see Recipes)

37. PTWH (see Recipes)

38. PTWH/5% DMSO/3% donkey serum (see Recipes)

39. PTWH/3% donkey serum (see Recipes)

Equipment

1. Forceps (Fine Science Tools, catalog number: 11252-00)

2. Benchtop rocker

3. Spring scissors (Fine Science Tools, catalog number: 15000-08))

4. Nikon microscope

5. Zeiss confocal microscope

Procedure

1. Sample preparation

   1. Prepare sylgard plate per manufacturer’s instruction. Once the sylgard plate is made, it can be used indefinitely.

   2. Dissect E14.5-E18.5 embryos from the uterus and remove extra embryonic membranes in ice-cold 1× PBS with forceps.

   3. Open the abdomen of the embryos and fix them in 1% PFA in a 12-well (E14.5 to E16.5) or 6-well (E17.5 to E18.5) plate overnight at 4°C.

   4. Wash embryos three times with 1× PBS on ice, 30 min each time (Figure 1A).

   5. Make incisions with spring scissors from the ears to just under the forelimbs (Figure 1B).

   6. Remove the skin carefully with forceps and try to take as little underlying tissue as possible (Figure 1C).

   7. Pin the skin on the sylgard plate and remove the connective tissue (arrows) with forceps (Figures 1D-1G).

   8. Remove the skin from sylgard plate and place in a 24-well plate for whole-mount immunostaining.

      
      

      
      Figure 1. Dermal skin preparation. A. E16.5 embryo fixed in PFA and ready for dorsal skin dissection. B. Incisions on the dorsal skin outlining the region that will be dissected out. C. Embryo after the removal of the dorsal skin. Notice that the underlying tissue was not significantly damaged by dissection. Subsequent cleaning steps are minimized when the skin is dissected out with the least amount of attached tissues. D. The skin sample was pinned onto the sylgard plate with the inside facing up. The arrows point to the collagen fibers that are attached to the skin. E-G. The same skin sample from which the connective tissue (arrows) is removed by peeling without damaging the underlying skin. The arrow in G indicates the connective tissue that can be discarded.

      
      

2. Whole-mount immunohistochemistry

   1. Wash the samples twice with 1 ml PBST, 30 min each time.

   2. Incubate samples in 1 ml PBST with 20% DMSO for 4 h.

   3. Incubate samples in 1 ml PTTDND overnight.

   4. Wash samples twice with 1 ml PBST, 30 min each time.

   5. Incubate samples in 1 ml 1 PTDG for 4 h.

   6. Block in 300 µl blocking buffer overnight.

   7. Wash twice with 1 ml PTWH, 30 min each time.

   8. Incubate with primary antibodies in 300 µl PTWH with 5% DMSO and 3% donkey serum overnight.

   9. Wash four times with 1 ml PTWH, 30 min each time.

   10. Incubate with secondary antibodies in 300 µl PTWH with 3% donkey serum overnight.

   11. Wash four times with 1 ml PTWH, 30 min each time.

   12. Wash twice with 1 ml 1× PBS, 10 min each time.

   13. Draw squares on the microscope slides with wax pen (Figures 2A and 2B).

   14. Add sufficient mounting media to the middle of the square (Figure 2B) and place the skin in the mounting media (Figure 2C). Let the inner side of the skin face up and position the anterior end (ears) of the dorsal skin towards the anterior end of the slide.

   15. Remove ears from the skin with spring scissors (Figure 2D).

   16. Overlay the sample with cover glass and gently press the skin by using the back of a forceps to smoothen out the wrinkles (Figure 2E).

   17. Seal the edges of the slides with nail polish and image under a fluorescent microscope (Figures 2F and 2G).

       
       

       
       Figure 2. Imaging the dermal skin. A. The dashed line on the slide indicates the approximate location of the chambers that will be made by outlining with the wax pen. B. After the outline is made with the wax pen, a drop of mounting media is placed in the middle of the chamber. C. Immunostained dorsal skin immersed in the mounting media with the inside of the skin facing up. D. Sample with ears carefully removed. E. Sample overlaid with a cover slip and gently pressed to remove air bubbles and wrinkles. F-G. Lower and higher magnification images of samples processed according to the described protocol. The VEGFR3+CD31+ (F) and VEGFR3+CD31+Prox1+ (G) structures are the lymphatic vessels. The SMA+ CD31+ vessels in F are the arteries and veins. The CD31+ vessels in G are the blood capillaries.

Notes

1. All washing and incubation steps are performed at room temperature using a benchtop rocker.

2. Step B2 can be shortened to 4 h.

3. This procedure may not be suitable for all antibodies. For example, the high concentration of detergents could disrupt the epitopes of some cell junction molecules. The user will have to perform preliminary experiments to determine the appropriateness of this protocol for their needs. Information about the antibodies that we have used is provided in Table 1. The antibody that did not work well with the iDISCO protocol is highlighted in red.

   
   

   Table 1. List of antibodies and conditions that can or cannot be used with the iDISCO protocol. The antibody that did not provide good signal when used with the described protocol is highlighted in red. The rest of the antibodies provide excellent results.
   

Recipes

1. 20× PBS

   Weigh 160 g NaCl, 4 g KCl, 28.8 g Na₂HPO₄, and 4.8 g KH₂PO₄. Transfer to a 1 L glass beaker. Add water to a volume of 900 ml. Mix and adjust pH to 7.4 with NaOH. Make up to 1 L with water. Autoclave.

2. 20% paraformaldehyde (PFA)

   Weigh 200 g PFA and transfer to a 1 L glass beaker. Add 500 ml water and stir with a magnetic stirrer on a hot plate in a fume hood. Heat the PFA suspension to 55-60°C (never over 60°C). Add 5 N NaOH in a drop wise manner until the suspension turns clear. Cool down the solution to room temperature. Add 50 ml of 20× PBS and adjust pH to 7.4 by adding 5 N NaOH in a drop wise manner. Make up to 1 L with water. Aliquot the solution with 50 ml falcon tubes and store at -20°C. Add 2.5 ml 20% PFA to 47.5 ml PBS to make 1% PFA.

3. 10% Triton X-100

   Mix 10 ml Triton X-100 with 90 ml water.

4. PBST (1× PBS with 0.2% Triton X-100)

   Mix 50 ml 20× PBS and 20 ml 10% Triton X-100 in a 1 L cylinder. Make up to 1 L with water.

5. PBST with 20% DMSO

   Mix 5 ml 20× PBS, 2 ml 10% Triton X-100, and 20 ml DMSO in 100 ml cylinder. Make up to 100 ml with water. Store in an amber glass bottle for up to 4 weeks.

6. 10% Tween 20

   Mix 10 ml Tween 20 with 90 ml water.

7. 10% NP40

   Mix 10 ml NP40 with 90 ml water.

8. PTTDND (1× PBS with 0.1% Tween-20, 0.1% TritonX-100, 0.1% Deoxycholate, 0.1% NP40, and 20% DMSO)

   Mix 5 ml 20× PBS, 20 ml DMSO, 1 ml 10% Triton 100, 1 ml 10% Tween 20, 1 ml 10% NP40, and 1 ml 10% sodium deoxycholate in 100 ml cylinder. Make up to 100 ml with water. Store in an amber glass bottle for up to 4 weeks.

9. 1 M glycine

   Dissolve 75 g in 800 ml water, add water to 1 L, and filter with 0.45 μm filter.

10. PTDG (1× PBS with 0.2% Triton X-100, 20% DMSO, and 0.3 M glycine)

    Mix 5 ml 20× PBS, 2 ml 10% Triton 100, 20 ml DMSO, and 30 ml 1 M glycine in 100 ml cylinder. Make up to 100 ml with water. Store in an amber glass bottle for up to 4 weeks.

11. Blocking buffer (1× PBS with 0.2% Triton X-100, 10% DMSO, and 6% donkey serum)

    To make 5 ml solution by mixing 4.1 ml 1× PBS, 0.1 ml 10% Triton 100, 0.5 ml DMSO, and 0.3 ml donkey serum. Make fresh each time.

12. PTWH (1× PBS with 0.2% Tween-20 and 10 µg/ml heparin)

    Mix 25 ml 20× PBS and 10 ml 10% Tween 20 in a 500 ml cylinder. Make up to 500 ml with water. Add 0.1 ml 50 mg/ml Heparin. Mix well and store in a glass bottle for up to 4 weeks.

13. PTWH with 5% DMSO and 3% donkey serum

    To make 5 ml solution, mix 0.15 ml donkey serum, 0.25 ml DMSO with 4.6 ml PTWH. Make fresh each time.

14. PTWH with 3% donkey serum

    To make 5 ml solution, mix 0.15 ml donkey serum with 4.85 ml PTWH. Make fresh each time.

Acknowledgments

This work is supported by NIH/NHLBI (R01HL131652 and R01HL133216 to RSS), NIH/NIGMS COBRE (P20 GM103441 to XG; PI: Dr. Rodger McEver), and Oklahoma Center for Adult Stem Cell Research (4340 to RSS) grants.

Competing interests

The authors declare no competing interests.

Ethics

Mice were handled in accordance with OMRF’s IACUC approval.

References

1. Betterman, K. L. and Harvey, N. L. (2018). Histological and morphological characterization of developing dermal lymphatic vessels. Methods Mol Biol 1846:19-35.
2. Cha, B., Geng, X., Mahamud, M. R., Fu, J., Mukherjee, A., Kim, Y., Jho, E. H., Kim, T. H., Kahn, M. L., Xia, L., Dixon, J. B., Chen, H. and Srinivasan, R. S. (2016). Mechanotransduction activates canonical wnt/beta-catenin signaling to promote lymphatic vascular patterning and the development of lymphatic and lymphovenous valves. Genes Dev 30(12): 1454-1469.
3. Cha, B., Geng, X., Mahamud, M. R., Zhang, J. Y., Chen, L., Kim, W., Jho, E. H., Kim, Y., Choi, D., Dixon, J. B., Chen, H., Hong, Y. K., Olson, L., Kim, T. H., Merrill, B. J., Davis, M. J. and Srinivasan, R. S. (2018). Complementary Wnt Sources Regulate Lymphatic Vascular Development via PROX1-Dependent Wnt/beta-Catenin Signaling. Cell Rep 25(3): 571-584 e575.
4. Cha, B., Ho, Y. C., Geng, X., Mahamud, M. R., Chen, L., Kim, Y., Choi, D., Kim, T. H., Randolph, G. J., Cao, X., Chen, H. and Srinivasan, R. S. (2020). YAP and TAZ maintain PROX1 expression in the developing lymphatic and lymphovenous valves in response to VEGF-C signaling. Development 147(23): dev195453.
5. Geng, X., Cha, B., Mahamud, M. R., Lim, K. C., Silasi-Mansat, R., Uddin, M. K. M., Miura, N., Xia, L., Simon, A. M., Engel, J. D., Chen, H., Lupu, F. and Srinivasan, R. S. (2016). Multiple mouse models of primary lymphedema exhibit distinct defects in lymphovenous valve development. Dev Biol 409(1): 218-233.
6. Geng, X., Yanagida, K., Akwii, R. G., Choi, D., Chen, L., Ho, Y., Cha, B., Mahamud, M. R., Berman de Ruiz, K., Ichise, H., Chen, H., Wythe, J. D., Mikelis, C. M., Hla, T. and Srinivasan, R. S. (2020). S1PR1 regulates the quiescence of lymphatic vessels by inhibiting laminar shear stress-dependent VEGF-C signaling. JCI Insight 5(14): e137652.
7. James, J. M., Nalbandian, A. and Mukouyama, Y. S. (2013). Tgfbeta signaling is required for sprouting lymphangiogenesis during lymphatic network development in the skin. Development. 140(18): 3903-3914.
8. Mahamud, M. R., Geng, X., Ho, Y. C., Cha, B., Kim, Y., Ma, J., Chen, L., Myers, G., Camper, S., Mustacich, D., Witte, M., Choi, D., Hong, Y. K., Chen, H., Varshney, G., Engel, J. D., Wang, S., Kim, T. H., Lim, K. C. and Srinivasan, R. S. (2019). GATA2 controls lymphatic endothelial cell junctional integrity and lymphovenous valve morphogenesis through miR-126. Development 146(21): dev184218.
9. Renier, N., Wu, Z., Simon, D. J., Yang, J., Ariel, P. and Tessier-Lavigne, M. (2014). Idisco: A simple, rapid method to immunolabel large tissue samples for volume imaging. Cell 159(4): 896-910.